EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Research advances and clinical prospects of CIGB-300, a novel CK2-targeted peptide inhibitor for cancer therapy

Wen Li

BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences · 26.06.2026

DOI: 10.70099/bj/2026.03.03.2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences, online erschienen am 26.06.2026. Verfasst von Wen Li. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Protein kinase CK2 is a constitutively active kinase that plays a central role in tumor progression, inhibition of apoptosis, and angiogenesis, making it a high-value target for cancer therapy. Unlike conventional ATP-competitive inhibitors, CIGB-300 is a first-in-class peptide inhibitor that operates through a dual mechanism, targeting both the CK2 substrate phosphoacceptor domain and the CK2α catalytic subunit. This letter summarizes the unique biological rationale for targeting CK2, the molecular properties and mechanism of CIGB-300, and the most recent preclinical and clinical evidence supporting its use. Preclinical studies demonstrate broad-spectrum antitumor activity and synergy with chemotherapeutic agents, while clinical trials have confirmed its safety, tolerability, and preliminary efficacy data in cervical cancer and other solid tumors. Current translational development at the China-Cuba Biotechnology Joint Innovation Center (CCBJIC), including IND-enabling studies and next-generation derivative programs, is actively advancing this promising peptide toward broader clinical application.

Zitieren

APA

Li, W. (2026). Research advances and clinical prospects of CIGB-300, a novel CK2-targeted peptide inhibitor for cancer therapy. BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences. https://doi.org/10.70099/bj/2026.03.03.2

Vancouver

Li W. Research advances and clinical prospects of CIGB-300, a novel CK2-targeted peptide inhibitor for cancer therapy. BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences. 2026. doi:10.70099/bj/2026.03.03.2

BibTeX
@article{Li2026,
  author = {Li, Wen},
  title = {Research advances and clinical prospects of CIGB-300, a novel CK2-targeted peptide inhibitor for cancer therapy},
  journal = {BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences},
  year = {2026},
  doi = {10.70099/bj/2026.03.03.2}
}
Kostenlos starten →